MANUFACTURING SCALE-UP - Co said increased expenses also reflected scale-up of commercial manufacturing facility
Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for EyePoint Inc is $39.00, about 234.2% above its August 4 closing price of $11.67
